1-7 of 7
Michael Robbins
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Genomic and Immunologic Analysis of Cmaf and Hypermutated Multiple Myeloma: Implications for Immunologic Therapy

Free
Hearn Jay Cho, MD PhD, Deepak Perumal, PhD, Adeeb H Rahman, PhD, Donald Jackson, PhD, Michael Robbins, PhD, Seunghee Kim-Schultze, PhD, Sacha Gnjatic, PhD, Samir Parekh, MD, Jonathan J Keats, PhD, Daniel Auclair
Journal: Blood
Blood (2019) 134 (Supplement_1): 3093.
https://doi.org/10.1182/blood-2019-131274
Published: 2019
Journal Articles

Comparative Analysis of sSLAMF7, sBCMA, and M-Protein As Prognostic, Predictive, and Pharmacodynamic Biomarkers in Relapsed/Refractory Multiple Myeloma Treated with Pomalidomide and Dexamethasone +/- Elotuzumab

Free
Ann Forslund, PhD, Hao Tang, Chunzhe Duan, Mihaela Popa-McKiver, PhD, James R. Berenson, MD, Michael Robbins, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1853.
https://doi.org/10.1182/blood-2019-128760
Published: 2019
Journal Articles

Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM

Free
Clinical Trials & Observations
Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K. Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying-Ming Jou, Michael Robbins, Antonio Palumbo
Journal: Blood
Blood (2016) 127 (23): 2833–2840.
https://doi.org/10.1182/blood-2016-01-694604
Published: 2016
Includes: Supplemental data
Journal Articles

Effects of Elotuzumab on Soluble SLAMF7 Levels in Multiple Myeloma

Free
Jennifer Postelnek, BA, James Sheridan, Steve Keller, Tatiana Pazina, MS, BS, Jennifer Sheng, Valerie Poulart, Michael Robbins, BS
Journal: Blood
Blood (2015) 126 (23): 2964.
https://doi.org/10.1182/blood.V126.23.2964.2964
Published: 2015
Journal Articles

Targeting Mechanisms for Natural Killer Cell Dysfunction in Patients with Multiple Myeloma

Free
Misty Jenkins, PhD, Rachael Canfield, BSc, Michael Robbins, BS, David S. Ritchie, MDPhD, Joe Trapani, Paul Neeson, BSc, PhD
Journal: Blood
Blood (2015) 126 (23): 4237.
https://doi.org/10.1182/blood.V126.23.4237.4237
Published: 2015
Journal Articles

Dissecting the Mechanisms of Activity of SLAMF7 and the Targeting Antibody Elotuzumab in Multiple Myeloma

Free
Siobhan Glavey, MD, Michaela Reagan, PhD, Salomon Manier, MD, Michele Moschetta, MD, Yawara Kawano, MDPhD, Antonio Sacco, BS, Aldo M Roccaro, MD PhD, Michael Robbins, BS, Irene M. Ghobrial, MD
Journal: Blood
Blood (2014) 124 (21): 3431.
https://doi.org/10.1182/blood.V124.21.3431.3431
Published: 2014
Journal Articles

Effects of IL-21, KIR Blockade, and CD137 Agonism on the Non-Clinical Activity of Elotuzumab

Free
Michael Robbins, BS, Maria Jure-Kunkel, DVM, PhD, Gennaro Dito, BS, Pascale Andre, PhD, Hui-fen Zhang, PhD, Natalie Bezman, PhD, Robert F Graziano, PhD
Journal: Blood
Blood (2014) 124 (21): 4717.
https://doi.org/10.1182/blood.V124.21.4717.4717
Published: 2014